Novartis has signed a global licensing agreement with Arrowhead Pharmaceuticals for the preclinical RNA interference (RNAi) therapy ARO-SNCA, targeting alpha-synuclein in Parkinson’s disease and related disorders. The deal, announced Tuesday and reported by Reuters, includes a $200 million upfront payment to Arrowhead, with up to $2 billion in potential milestones, plus tiered royalties (capped in… The post Novartis bets $200M upfront on Arrowhead’s Parkinson’s RNAi, total value up to...
